Senseonics Eversense 365 (European Launch)

Continuous glucose monitoring has been an incremental business for years: sensors got a little smaller, a little longer-lived, a little more accurate. The Eversense 365 is not incremental. It is an implantable sensor rated for a full year of wear, which means a single clinical procedure replaces roughly two dozen self-applied sensor changes annually. Senseonics has been building toward this since the six-month Eversense E3, and doubling that lifespan while cutting fingerstick calibration from daily to weekly is the kind of quality-of-life change patients actually notice day to day.

This is squarely aimed at people with Type 1 or Type 2 diabetes who are committed long-term CGM users and who find the adhesive-and-applicator routine of disposable sensors tiresome, irritating to the skin, or simply hard to keep on. It is emphatically not a casual purchase: insertion and removal are clinical procedures, and you are signing up for a relationship with a provider rather than a subscription box. Europeans should also temper expectations on timing — the launch began in Sweden in April 2026 following January's CE Mark, with Germany, Spain and Italy following in phases, so availability will be patchy for a while.

On the evidence supplied, the Eversense 365 is the most interesting thing to happen to CGM form factors in years, and the once-weekly calibration is what makes the one-year claim practical rather than merely impressive on a spec sheet. A daily fingerstick tax, as on the E3, would have undercut much of the convenience; weekly is a reasonable trade for never touching an applicator again. That Senseonics already has U.S. approval behind it and an announced integration with Sequel Med Tech's twiist automated insulin delivery system suggests this is a maturing platform rather than a first-generation experiment, though that integration is a U.S. story for now.

What keeps the score where it is, however, is how much we simply don't know. There is no published price, no stated accuracy figure, no detail on the transmitter, app, alerts or battery behaviour, and no description of what insertion and removal actually involve. For a device that lives under your skin for twelve months, those are not footnotes — they are the review. The company's own framing of a 30-million-patient addressable market is a growth narrative, not a patient benefit, and the one-year real-world performance data referenced at ATTD is cited but not detailed here.

The verdict, then, is a confident yes on the concept and a firm "not yet" on the full assessment. If a year-long implant appeals and you are in one of the launch markets, this is worth raising with your diabetes team. We'd want pricing, reimbursement clarity and independent accuracy data before recommending it over well-established disposable systems.

• Rating rationale: a genuinely novel, well-differentiated product held back from a higher score by unpublished pricing, accuracy and usability detail, plus limited initial availability.